Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 49

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants

Restle, Anja, Färber, Martin, Baumann, Cindy, Böhringer, Michael, Scheidtmann, Karl Heinz, Müller-Tidow, Carsten, Wiesmüller, Lisa · 2008 · Nucleic Acids Research

Abstract

Regulation of homologous recombination (HR) represents the best-characterized DNA repair function of p53. The role of p53 phosphorylation in DNA repair is largely unknown. Here, we show that wild-type p53 repressed repair of DNA double-strand breaks (DSBs) by HR in a manner partially requiring the ATM/ATR phosphorylation site, serine 15. Cdk-mediated phosphorylation of serine 315 was dispensable for this anti-recombinogenic effect. However, without targeted cleavage of the HR substrate, serine 315 phosphorylation was necessary for the activation of topoisomerase I-dependent HR by p53. Moreover, overexpression of cyclin A1, which mimics the situation in tumors, inappropriately stimulated DSB-induced HR in the presence of oncogenic p53 mutants (not Wtp53). This effect required cyclin A1/cdk-mediated phosphorylation for stable complex formation with topoisomerase I. We conclude that p53 mutants have lost the balance between activation and repression of HR, which results in a net increase of potentially mutagenic DNA rearrangements. Our data provide new insight into the mechanism underlying gain-of-function of mutant p53 in genomic instability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkn503

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. HR analysis after expression of p53 proteins mutated on N- and C-terminal phosphorylation sites. (A) Schematic drawing of the HR assay substrate HR-EGFP/3′EGFP, which allows to quantify homologous DSB repair by FACS after I-SceI-mediated cleavage (21). (B) KMV(HR/3′) cells were electroporated with pCMV-I-SceI, and pKEX (control) or pKEX derivatives for the expression of Wt and mutant (174Y, 15A, 4/6A, 390A, 310/313A) p53 from rat, and cultivated for 72 h. Recombination frequencies were determined as the fraction of green fluorescent cells compared to the total cell population and normalized in each case to the individual transfection efficiency. Columns, mean (n = 6); bars, SEM. (C) Total cell homogenates were prepared from transfected KMV(HR/3′) cells and the amounts of p53, p21 and RAD51 were analyzed by immunoblotting.
Figure 1. HR analysis after expression of p53 proteins mutated on N- and C-terminal phosphorylation sites. (A) Schematic drawing of the HR assay substrate HR-EGFP/3′EGFP, which allows to quantify homologous DSB repair by FACS after I-SceI-mediated cleavage (21). (B) KMV(HR/3′) cells were electroporated with pCMV-I-SceI, and pKEX (control) or pKEX derivatives for the expression of Wt and mutant (174Y, 15A, 4/6A, 390A, 310/313A) p53 from rat, and cultivated for 72 h. Recombination frequencies were determined as the fraction of green fluorescent cells compared to the total cell population and normalized in each case to the individual transfection efficiency. Columns, mean (n = 6); bars, SEM. (C) Total cell homogenates were prepared from transfected KMV(HR/3′) cells and the amounts of p53, p21 and RAD51 were analyzed by immunoblotting.CC BY-NC · PubMed Central
Figure 2. Influence of ATM/ATR-mediated phosphorylation. (A) Homologous DSB repair of chromosomal substrates was assayed in KMV(HR/3′) cells as in Figure 1 using the following expression plasmids for human p53 fused to the human estrogen receptor hormone-binding domain: pSVp53her (Wt), pSVp53(15A)her, pSVp53(1-333)her or pBS (control) in the absence or presence of 400 μM caffeine (A) or 2 μM CGK (B). Recombination frequencies in cells without p53 were set to 100% [absolute mean value in (A) and (B): 1.0 × 10−3]. Columns, mean (n = 3–9); bars, SEM. (C) Equal expression of p53her and p53(15A)her and decreased phosphorylation of p53her at serine 15 after caffeine and CGK treatment, respectively.
Figure 2. Influence of ATM/ATR-mediated phosphorylation. (A) Homologous DSB repair of chromosomal substrates was assayed in KMV(HR/3′) cells as in Figure 1 using the following expression plasmids for human p53 fused to the human estrogen receptor hormone-binding domain: pSVp53her (Wt), pSVp53(15A)her, pSVp53(1-333)her or pBS (control) in the absence or presence of 400 μM caffeine (A) or 2 μM CGK (B). Recombination frequencies in cells without p53 were set to 100% [absolute mean value in (A) and (B): 1.0 × 10−3]. Columns, mean (n = 3–9); bars, SEM. (C) Equal expression of p53her and p53(15A)her and decreased phosphorylation of p53her at serine 15 after caffeine and CGK treatment, respectively.CC BY-NC · PubMed Central
Figure 3. HR regulation upon mutation of C-terminal p53 phosphorylation sites. (A) Chromosomal homologous DSB repair using human p53 expression plasmid pCMV-p53(273H), pCMV-Wtp53, pCMV-p53(315A), pCMV-p53(392A), pCMV-p53(392D) or empty vector (control). Recombination frequencies in cells without p53 were set to 100% (absolute mean value: 2.0 × 10−3). Columns, mean (n = 6–12); bars, SEM. (B) Western blot analysis of p53, RAD51 and p21.
Figure 3. HR regulation upon mutation of C-terminal p53 phosphorylation sites. (A) Chromosomal homologous DSB repair using human p53 expression plasmid pCMV-p53(273H), pCMV-Wtp53, pCMV-p53(315A), pCMV-p53(392A), pCMV-p53(392D) or empty vector (control). Recombination frequencies in cells without p53 were set to 100% (absolute mean value: 2.0 × 10−3). Columns, mean (n = 6–12); bars, SEM. (B) Western blot analysis of p53, RAD51 and p21.CC BY-NC · PubMed Central
Figure 4. p53-mediated regulation of HR after knockdown of topo I. (A) and (B) KMV(HR/3′) cells were transfected with pCMV-Wtp53, pCMV-p53(315A), pCMV-p53(273H), pCMV-p53(248W) or empty vector (control) and pSUPER (−) or pSUPER-TopoI (+) for topo I-specific RNA interference, and subjected to HR-measurements. For I-SceI-mediated substrate cleavage in (B), pCMV-I-SceI was included in the transfection mixture. Recombination frequencies of p53-negative cells with pSUPER were set to 100% (absolute mean values: 2.7 × 10−5 without I-SceI and 2.0 × 10−3 with I-SceI). Columns, mean values of 12 to 41 (A) and six (B) measurements, respectively; bars, SEM.
Figure 4. p53-mediated regulation of HR after knockdown of topo I. (A) and (B) KMV(HR/3′) cells were transfected with pCMV-Wtp53, pCMV-p53(315A), pCMV-p53(273H), pCMV-p53(248W) or empty vector (control) and pSUPER (−) or pSUPER-TopoI (+) for topo I-specific RNA interference, and subjected to HR-measurements. For I-SceI-mediated substrate cleavage in (B), pCMV-I-SceI was included in the transfection mixture. Recombination frequencies of p53-negative cells with pSUPER were set to 100% (absolute mean values: 2.7 × 10−5 without I-SceI and 2.0 × 10−3 with I-SceI). Columns, mean values of 12 to 41 (A) and six (B) measurements, respectively; bars, SEM.CC BY-NC · PubMed Central
Figure 5. Effect of cyclin A1 and A2 on homologous DSB repair in cells differing in their p53 and topo I status. (A) DSB-induced HR was determined in KMV(HR/3′) cells cotransfected with pCMV-I-SceI, and pCMV-Wtp53, pCMV-p53(315A), pCMV-p53(273H), pCMV-p53(248W) or empty vector (control), and pcDNA3-cyclin A1 (A1), pCMV-cyclin A2 (A2) or empty vector (−). Columns, mean (n = 12–27); bars, SEM. (B) DSB-induced HR in cells overexpressing cyclin A1, cotransfected with pSUPER (−) or pSUPER-TopoI (+). Columns, mean (n = 12–18); bars, SEM. (C) DSB-induced HR in cells overexpressing cyclin A2, cotransfected with pSUPER (−) or pSUPER-TopoI (+). Columns, mean (n = 6); bars, SEM. Recombination frequencies in controls were set to 100% (absolute mean value in (A) −p53/−cyclins: 2.1 × 10−3; in (B) −p53/+cyclin A1/−pSUPER-TopoI: 2.2 × 10−3; in (C) −p53/+cyclin A2/−pSUPER-TopoI: 2.8 × 10−3). (D) pSUPER-TopoI-mediated downregulation of topo I protein compared to p53 expression. (E) Western blotting of cyclin A1 and cyclin A2.
Figure 5. Effect of cyclin A1 and A2 on homologous DSB repair in cells differing in their p53 and topo I status. (A) DSB-induced HR was determined in KMV(HR/3′) cells cotransfected with pCMV-I-SceI, and pCMV-Wtp53, pCMV-p53(315A), pCMV-p53(273H), pCMV-p53(248W) or empty vector (control), and pcDNA3-cyclin A1 (A1), pCMV-cyclin A2 (A2) or empty vector (−). Columns, mean (n = 12–27); bars, SEM. (B) DSB-induced HR in cells overexpressing cyclin A1, cotransfected with pSUPER (−) or pSUPER-TopoI (+). Columns, mean (n = 12–18); bars, SEM. (C) DSB-induced HR in cells overexpressing cyclin A2, cotransfected with pSUPER (−) or pSUPER-TopoI (+). Columns, mean (n = 6); bars, SEM. Recombination frequencies in controls were set to 100% (absolute mean value in (A) −p53/−cyclins: 2.1 × 10−3; in (B) −p53/+cyclin A1/−pSUPER-TopoI: 2.2 × 10−3; in (C) −p53/+cyclin A2/−pSUPER-TopoI: 2.8 × 10−3). (D) pSUPER-TopoI-mediated downregulation of topo I protein compared to p53 expression. (E) Western blotting of cyclin A1 and cyclin A2.CC BY-NC · PubMed Central
Figure 6. Influence of cdk inhibition on HR regulation by cyclin A1 and mutant p53. (A) DSB-induced HR in KMV(HR/3′) cells treated with DMSO (−) or 80 μM olomoucine (+). Recombination frequencies in controls −p53/−cyclin A1/−olomoucine were set to 100% (absolute mean value: 1.1 × 10−3). Columns, mean (n = 12–18); bars, SEM. (B) Immunoblot analysis for p53pSer315 and p53. (C) Cell-cycle analysis. Columns, mean (n = 2); bars, SD.
Figure 6. Influence of cdk inhibition on HR regulation by cyclin A1 and mutant p53. (A) DSB-induced HR in KMV(HR/3′) cells treated with DMSO (−) or 80 μM olomoucine (+). Recombination frequencies in controls −p53/−cyclin A1/−olomoucine were set to 100% (absolute mean value: 1.1 × 10−3). Columns, mean (n = 12–18); bars, SEM. (B) Immunoblot analysis for p53pSer315 and p53. (C) Cell-cycle analysis. Columns, mean (n = 2); bars, SD.CC BY-NC · PubMed Central
Figure 7. Regulation of HR by cyclin A1 and mutant p53 after knockdown of cdk2. (A) DSB-induced HR in KMV(HR/3′) cells cotransfected with empty vector or pKD-cdk2-v5 (pKD-cdk2) for cdk2-specific RNA interference. Recombination frequencies in controls −p53/−cyclin A1/−pKD-cdk2 were set to 100% (absolute mean value: 1.2 × 10−3). Columns, mean (n = 6); bars, SEM. (B) Western blot analysis of cdk2.
Figure 7. Regulation of HR by cyclin A1 and mutant p53 after knockdown of cdk2. (A) DSB-induced HR in KMV(HR/3′) cells cotransfected with empty vector or pKD-cdk2-v5 (pKD-cdk2) for cdk2-specific RNA interference. Recombination frequencies in controls −p53/−cyclin A1/−pKD-cdk2 were set to 100% (absolute mean value: 1.2 × 10−3). Columns, mean (n = 6); bars, SEM. (B) Western blot analysis of cdk2.CC BY-NC · PubMed Central
Figure 8. Coimmunoprecipitation of topo I and p53 is enhanced by cyclin A1. KMV(HR/3′) cells were electroporated with pCMV-I-SceI plus empty expression vector (control), pCMV-p53(248W) or pCMV-Wtp53 plus empty vector or pcDNA3-cyclin A1, and treated with DMSO (−) or 80 μM olomoucine, exactly as described in Figure 6. Twenty-four hours later, whole-cell extracts were prepared without [p53(248W)] or with (Wtp53) cross-linking of chromatin complexes in vivo and topo I immunoprecipitated with Scl-70 serum followed by western blotting for p53 or topo I. As a negative control for nonspecific topo I interactions, the extract was immunoprecipitated with anti-GAPDH antibodies (IgG). Nonspecific signals in the western blot from the heavy chain with a molecular mass similar to p53 were excluded by the empty vector controls.
Figure 8. Coimmunoprecipitation of topo I and p53 is enhanced by cyclin A1. KMV(HR/3′) cells were electroporated with pCMV-I-SceI plus empty expression vector (control), pCMV-p53(248W) or pCMV-Wtp53 plus empty vector or pcDNA3-cyclin A1, and treated with DMSO (−) or 80 μM olomoucine, exactly as described in Figure 6. Twenty-four hours later, whole-cell extracts were prepared without [p53(248W)] or with (Wtp53) cross-linking of chromatin complexes in vivo and topo I immunoprecipitated with Scl-70 serum followed by western blotting for p53 or topo I. As a negative control for nonspecific topo I interactions, the extract was immunoprecipitated with anti-GAPDH antibodies (IgG). Nonspecific signals in the western blot from the heavy chain with a molecular mass similar to p53 were excluded by the empty vector controls.CC BY-NC · PubMed Central
Figure 9. Proposed model of a cyclin A1-induced mechanism leading to genomic instability by oncogenic mutant p53.
Figure 9. Proposed model of a cyclin A1-induced mechanism leading to genomic instability by oncogenic mutant p53.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 58

  1. Vogelstein, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
  2. Saito, 2003, Phosphorylation site interdependence of human p53 post-translational modifications in response to stress, J. Biol. Chem., 278, 37536, 10.1074/jbc.M305135200 · DOI · Paper page
  3. Fuchs, 1995, p53 phosphorylation mutants retain transcription activity, Oncogene, 10, 789
  4. Thompson, 2004, Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis, J. Biol. Chem., 279, 53015, 10.1074/jbc.M410233200 · DOI · Paper page
  5. Jackson, 2004, Limited role of N-terminal residues in the activation of transcription by p53, Oncogene, 23, 4477, 10.1038/sj.onc.1207575 · DOI
  6. Sengupta, 2003, BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination, EMBO J., 22, 1210, 10.1093/emboj/cdg114 · DOI · Paper page
  7. Restle, 2005, Differences in the association of p53 phosphorylated on serine 15 and key enzymes of homologous recombination, Oncogene, 24, 4380, 10.1038/sj.onc.1208639 · DOI
  8. Linke, 2003, p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination, Cancer Res., 63, 2596
  9. Bertrand, 2004, P53's double life: transactivation-independent repression of homologous recombination, Trends Genet., 20, 235, 10.1016/j.tig.2004.04.003 · DOI
  10. Arias-Lopez, 2006, p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene, EMBO Rep., 7, 219, 10.1038/sj.embor.7400587 · DOI · Paper page
  11. Boehden, 2005, Wild-type p53 stimulates homologous recombination upon sequence-specific binding to the ribosomal gene cluster repeat, Oncogene, 24, 4183, 10.1038/sj.onc.1208592 · DOI
  12. Boehden, 2004, Recombination at chromosomal sequences involved in leukaemogenic rearrangements is differentially regulated by p53, Carcinogenesis, 25, 1305, 10.1093/carcin/bgh092 · DOI
  13. Baumann, 2006, Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by p53, Nucleic Acids Res., 34, 1036, 10.1093/nar/gkj509 · DOI
  14. Subramanian, 2005, Modulation of p53 binding to Holliday junctions and 3-cytosine bulges by phosphorylation events, Biochemistry, 44, 2536, 10.1021/bi048700u · DOI
  15. Akyüz, 2002, DNA substrate dependence of the p53-mediated regulation of double-strand break repair, Mol. Cell Biol., 22, 6306, 10.1128/MCB.22.17.6306-6317.2002 · DOI · Paper page
  16. Brummelkamp, 2002, A system for stable expression of short interfering RNAs in mammalian cells, Science, 296, 550, 10.1126/science.1068999 · DOI · Paper page
  17. Müller-Tidow, 2004, The cyclin A1-CDK2 complex regulates DNA double-strand break repair, Mol. Cell Biol., 24, 8917, 10.1128/MCB.24.20.8917-8928.2004 · DOI
  18. Lambert, 2000, Characterization of mammalian RAD51 double strand break repair using non-lethal dominant-negative forms, EMBO J., 19, 3090, 10.1093/emboj/19.12.3090 · DOI
  19. Grandori, 2003, Werner syndrome protein limits MYC-induced cellular senescence, Genes Dev., 17, 1569, 10.1101/gad.1100303 · DOI · Paper page
  20. Zink, 2002, Association of p53 and MSH2 with recombinative repair complexes during S-phase, Oncogene, 21, 4788, 10.1038/sj.onc.1205614 · DOI
  21. Sarkaria, 1999, Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine, Cancer Res., 59, 4375
  22. Mahdi, 1998, Rescue of K562 cells from MDM2-modulated p53-dependent apoptosis by growth factor-induced differentiation, Biol. Chem., 90, 15
  23. Saintigny, 1999, Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint, Oncogene, 18, 3553, 10.1038/sj.onc.1202941 · DOI
  24. Won, 2006, Small molecule-based reversible reprogramming of cellular lifespan, Nat. Chem. Biol., 2, 369, 10.1038/nchembio800 · DOI
  25. Gobert, 1999, The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53, Proc. Natl Acad. Sci. USA, 96, 10355, 10.1073/pnas.96.18.10355 · DOI
  26. Boehden, 2003, p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair, Oncogene, 22, 4111, 10.1038/sj.onc.1206632 · DOI
  27. Wesierska-Gadek, 2004, Cell cycle arrest induced in human breast cabcer celly by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine, Pol. J. Pharmacol., 56, 635
  28. Rothkamm, 2003, Pathways of DNA double-strand break repair during the mammalian cell cycle, Mol. Cell Biol., 23, 5706, 10.1128/MCB.23.16.5706-5715.2003 · DOI · Paper page
  29. Fogal, 2005, Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315, EMBO J., 24, 2768, 10.1038/sj.emboj.7600735 · DOI
  30. Yang, 1999, Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins, Mol. Cell Biol., 19, 2400, 10.1128/MCB.19.3.2400 · DOI
  31. Blander, 1999, Physical and functional interaction between p53 and the Werner's syndrome protein, J. Biol. Chem., 274, 29463, 10.1074/jbc.274.41.29463 · DOI · Paper page
  32. Lebel, 1999, The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I, J. Biol. Chem., 274, 37795, 10.1074/jbc.274.53.37795 · DOI · Paper page
  33. Laine, 2003, Werner protein stimulates topoisomerase I DNA relaxation activity, Cancer Res., 63, 7136
  34. Song, 2007, p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nat. Cell Biol., 9, 573, 10.1038/ncb1571 · DOI · Paper page
  35. El-Hizawi, 2002, Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins, Cancer Res., 62, 3264
  36. Perkins, 2002, Sensing of intermediates in V(D)J recombination by ATM, Genes Dev., 16, 159, 10.1101/gad.956902 · DOI
  37. Romanova, 2004, The interaction of p53 with replication protein A mediates suppression of homologous recombination, Oncogene, 23, 9025, 10.1038/sj.onc.1207982 · DOI · Paper page
  38. Sengupta, 2004, Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest, J. Cell Biol., 166, 801, 10.1083/jcb.200405128 · DOI
  39. Wang, 1995, Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases, Nature, 376, 88, 10.1038/376088a0 · DOI · Paper page
  40. Luciani, 2000, The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A, J. Mol. Biol., 300, 503, 10.1006/jmbi.2000.3830 · DOI
  41. Larsen, 1999, DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde ?, Pathol. Oncol. Res., 5, 171, 10.1053/paor.1999.0209 · DOI
  42. Champoux, 1977, Strand breakage by the DNA untwisting enzyme results in covalent attachment of the enzyme to DNA, Proc. Natl Acad. Sci. USA, 74, 3800, 10.1073/pnas.74.9.3800 · doi:10.1073/pnas.74.9.3800
  43. Sekiguchi, 1996, Resolution of Holliday junctions by eukaryotic DNA topoisomerase I, Proc. Natl Acad. Sci. USA, 93, 785, 10.1073/pnas.93.2.785 · DOI
  44. Liao, 2004, Resolution of undistorted symmetric immobile DNA junctions by vaccinia topoisomerase I, Biochemistry, 43, 1520, 10.1021/bi0358061 · doi:10.1021/bi0358061
  45. Gobert, 1996, Modulation of DNA topoisomerase I activity by p53, Biochemistry, 35, 5778, 10.1021/bi952327w · DOI
  46. Albor, 1998, Wildtype and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants, Cancer Res., 5, 2091
  47. Stephan, 2002, Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro, Nucleic Acids Res., 30, 5087, 10.1093/nar/gkf659 · doi:10.1093/nar/gkf659
  48. Roemer, 1999, Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators, Biol. Chem., 380, 879, 10.1515/BC.1999.108 · DOI
  49. Liu, 1996, Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations, Oncogene, 12, 2267
  50. Murphy, 2000, Mutant p53 and genomic instability in a transgenic mouse model of breast cancer, Oncogene, 19, 1045, 10.1038/sj.onc.1203274 · DOI
  51. Müller, 1999, c-myb transactivates the human cyclin A1 promoter and induces cyclin A1 gene expression, Blood, 94, 4255, 10.1182/blood.V94.12.4255 · DOI
  52. Müller, 2000, The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia, Blood, 96, 3894, 10.1182/blood.V96.12.3894 · DOI
  53. Coletta, 2004, The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1, Proc. Natl Acad. Sci. USA, 101, 6478, 10.1073/pnas.0401139101 · DOI · Paper page
  54. Müller-Tidow, 2003, Cyclin A1 is highly expressed in aggressive testicular germ cell tumors, Cancer Lett., 190, 89, 10.1016/S0304-3835(02)00582-7 · doi:10.1016/s0304-3835(02)00582-7
  55. Yang, 1999, Cyclin A1 expression in leukemia and normal hematopoietic cells, Blood, 93, 2067
  56. Liao, 2001, Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1, Proc. Natl Acad. Sci. USA, 98, 6853, 10.1073/pnas.121540098 · DOI
  57. Tokumaru, 2004, Inverse correlation between cyclin A1 hyper-methylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing, Cancer Res., 64, 5982, 10.1158/0008-5472.CAN-04-0993 · DOI
  58. Armata, 2007, The ataxia telangiectasia-mutated target site ser18 is required for p53-mediated tumor suppression, Cancer Res., 67, 11696, 10.1158/0008-5472.CAN-07-1610 · DOI

Cited by

Metadata

Authors
Restle, A., Färber, M., Baumann, C., Böhringer, M., Scheidtmann, K. H., Müller-Tidow, C., & Wiesmüller, L.
Affiliations
  • Department of Obstetrics and Gynecology, University of Ulm, 89075 Ulm,
  • Institute for Genetics, University of Bonn, 53113 Bonn
  • Department of Medicine, Hematology/Oncology, University of Münster, 48129 Münster, Germany
Venue
Nucleic Acids Research
Published
2008-08-12
Volume
36
Issue
16
Pages
5362-5375
ISSN
  • 1362-4962
  • 0305-1048
Cited by
49
References
10
Language
en
Funders
  • Deutsche Forschungsgemeinschaft (Wi 1376/3-2, Wi 3099/7-1)
  • Landesstiftung Baden-Württemberg (10-1907-Wi 2)
  • Dr Mildred Scheel Stiftung für Krebsforschung (107744)
  • University of Ulm, Germany

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.